KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 5.11%.

  • Jazz Pharmaceuticals' EBITDA Margin fell 195600.0% to 5.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.46%, marking a year-over-year decrease of 217000.0%. This contributed to the annual value of 17.61% for FY2024, which is 25200.0% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported EBITDA Margin of 5.11% as of Q3 2025, which was down 195600.0% from 65.64% recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' EBITDA Margin peaked at 26.68% during Q1 2021, and registered a low of 65.64% during Q2 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 9.96% (2022), whereas its average is 5.04%.
  • Per our database at Business Quant, Jazz Pharmaceuticals' EBITDA Margin skyrocketed by 621500bps in 2021 and then tumbled by -851200bps in 2025.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' EBITDA Margin stood at 5.51% in 2021, then crashed by -592bps to 27.09% in 2022, then skyrocketed by 145bps to 12.11% in 2023, then skyrocketed by 45bps to 17.53% in 2024, then crashed by -71bps to 5.11% in 2025.
  • Its EBITDA Margin stands at 5.11% for Q3 2025, versus 65.64% for Q2 2025 and 17.53% for Q4 2024.